Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;38(5):940-2.
doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Jay M Sosenko  1 , Jay S Skyler  2 , Craig A Beam  3 , David Boulware  4 , Jeffrey L Mahon  5 , Jeffrey P Krischer  4 , Carla J Greenbaum  6 , Lisa E Rafkin  2 , Della Matheson  2 , Kevan C Herold  7 , Jerry P Palmer  8 ; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups
Collaborators, Affiliations

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Jay M Sosenko et al. Diabetes Care. 2015 May.

Abstract

Objective: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.

Research design and methods: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.

Results: The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all).

Conclusions: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Three-year risk estimates are shown according to PS6M categories. The 3-year risk estimates are low until PS6M values are above zero and then increase substantially with increasing PS6M values.
See this image and copyright information in PMC

References

    1. Diabetes Prevention Trial–Type 1 Diabetes Study Group . Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685–1691 - PubMed
    1. Skyler JS, Krischer JP, Wolfsdorf J, et al. . Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial–Type 1. Diabetes Care 2005;28:1068–1076 - PubMed
    1. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group . European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925–931 - PubMed
    1. Sosenko JM, Palmer JP, Greenbaum CJ, et al. . Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643–649 - PubMed
    1. Sosenko JM, Palmer JP, Rafkin LE, et al. .; Diabetes Prevention Trial-Type 1 Study Group . Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 participants. Diabetes Care 2010;33:620–625 - PMC - PubMed

Publication types